A Case Report of a Poor Metabolizer of CYP2D6 Presented with Unusual Responses to Nortriptyline Medication.
10.3346/jkms.2004.19.5.750
- Author:
Soo Youn LEE
1
;
Chang Seok KI
;
Kyung Sue HONG
;
Jong Won KIM
Author Information
1. Department of Laboratory Medicine, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Korea. jwonk@smc.samsung.co.kr
- Publication Type:Case Report
- Keywords:
Nortriptyline;
Cytochrome P-450 CYP2D6;
Adverse effects;
Pharmacogenetics
- MeSH:
Antidepressive Agents, Tricyclic/*adverse effects/pharmacokinetics;
Cytochrome P-450 CYP2D6/*genetics/metabolism;
Depression/*drug therapy/genetics;
Genotype;
Humans;
Male;
Middle Aged;
Nortriptyline/*adverse effects/pharmacokinetics
- From:Journal of Korean Medical Science
2004;19(5):750-752
- CountryRepublic of Korea
- Language:English
-
Abstract:
We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT). Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B. This case suggests the clinical usefulness of pharmacogenetic testing in individualized dosage adjustments of NT.
